http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2445974-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_30d37bedd5e7ec93119e04b7401eb2fe |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-16 |
| filingDate | 2010-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5521e9e0c4fe0ce204ef2c82e5e4bdad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cdb8676e9378dd90f4364835ceb28bc5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_780279ade494f99e98884c9829b02ff2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e2dbf2e93a4a0fe57874297b4d14cc0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3658187d460df8783d035aed71b4e70f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dda050d7dbbfec6c8d0223b9cb83d561 |
| publicationDate | 2012-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2445974-C2 |
| titleOfInvention | Method for producing concentrated factor viii of human blood plasma |
| abstract | FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to medicine and describes a method for recovery of factor VIII from human blood plasma not identified by related analysis of hepatitis and HIV1/2 viruses consisting in sequential cryoprecipitation, dissolution in an aqueous solution of heparin and solubilisation of a cryoprecipitate, sorption of a prothrombin-converting complex factor by aluminium hydrate, removal of fibrinogen, fibronectin and associated protein by polyethylene glycol-4000, viral inactivation with solvent detergents and preliminary filtration, anion-exchange chromatography, preferentially with EDM-TMAE Fractogel, with elution by a sodium chloride buffer, stabilisation by albumine solution, sterile filtration in membrane filters of pore diameter 0.22 mcm, bottling (200-300 IU/bottle), lyophilisation and second thermal viral inactivation with purification using the aqueous solution of unfractionated heparin of the concentrations equal to 5-100 international units (IU)/ml, preferentially 10-25 IU/ml, polyethylene glycol-4000 in the final concentration 3.5% and acidification of the medium, preferentially to pH 6.6, strong TMAE anion exchangers. n EFFECT: method substantially provides higher effectiveness of purification and specific activity of factor VIII. n 1 tbl, 4 dwg, 2 ex |
| priorityDate | 2010-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 101.